Automated literature review and the meta-analysis of the results of scientific studies using AI-driven systems represent a significant shift in how scientific knowledge is synthesized and utilized. These systems can process and analyze vast amounts of published research at speeds and scales unachievable by human efforts alone. By identifying patterns, trends, and anomalies within extensive datasets, AI can consistently offer comprehensive, up-to-date summaries and insights. This capability is especially crucial in fields like medicine and environmental science, where rapid advancements can have immediate implications on policy and practice.

One major area of impact is the enhancement of research efficiency. Now, researchers can devote more time to experimental design and data interpretation rather than sifting through literature, which is accelerating the pace of scientific discovery. These AI systems also promote a more interconnected scientific community. By breaking down barriers related to the accessibility of knowledge, they enable a democratization of information, allowing for a broader base of scientists to engage with cutting-edge research regardless of geographical or institutional boundaries.

Systematic reviews are the most objective and transparent way of synthesizing information originating from evidence-based medicine, and AI is facilitating and drastically accelerating this process. For example, Insilica’s SysRev⁵ has enabled more than 16,000 systematic review projects in the last 5 years. Equally, AI-driven platforms like Iris.ai⁶, Elicit.ai⁷ or Semantic Scholar⁸, or the ORKG ASK platform developed by the TIB Leibniz Information Centre for Science and Technology, which provides an open-source infrastructure for semantically enriched scholarly search and question answering⁹, facilitate comprehensive literature reviews by mapping out relevant studies and reducing reading time. PubMed, another example, uses AI for query manipulation, author name disambiguation, and automatic indexing of articles. PubMed for example uses AI for Best Match, query manipulation, author name disambiguation, and automatic indexing of articles (Kiester and Turp, 2022).

However, the reliance on AI for literature review also introduces challenges, including the need for open access publishing, consistently high-quality data inputs, and the potential for algorithmic biases. Ensuring the accuracy, fairness, and transparency of AI-driven reviews is essential to maintain scientific integrity and trust in AI-facilitated research methodologies. However, the value of comprehensive literature assessments and the increasingly systematic review of the body of existing knowledge is an enormous value proposition of AI-based literature analyses. A meta-analysis by Doneva et al. (2024) underscores just how far the field has leapt: powered by an LLM-centric pipeline the team screened and extracted data from more than five-hundred pharmacogenomics papers, lifting F1 scores a full ten points above rule-based baselines and completing the entire review in under a week.

The use of LLMs for hypothesis generation marks a transformative advancement in scientific research methodologies. By analyzing existing datasets, these AI-driven systems can propose new scientific hypotheses, uncovering potential areas of investigation that might remain hidden using traditional analytical methods. This capability accelerates the discovery process and enhances the creativity and scope of scientific inquiry.

A significant benefit of LLMs in hypothesis generation is their ability to integrate and synthesize diverse data types from varied sources. This can lead to the growth of interdisciplinary research approaches, bridging gaps between distinct scientific domains and fostering innovative solutions to complex problems. Additionally, LLMs can identify subtle correlations and patterns that human researchers might overlook and propose novel hypotheses that can lead to breakthroughs in understanding and technology.

Examples of developments that highlight AI’s role in enhancing scientific understanding and innovation include, for instance, Placek et al. (2021) identify genes potentially linked to Amyotrophic Lateral Sclerosis (ALS), offering new research pathways. The paper uses sparse canonical correlation analysis (sCCA)—a machine learning method—to analyze genetic data in relation to cognitive outcomes in ALS patients. This is in enabling data-driven generation of a weighted polygenic risk score (wPRS). The use of AI to translate complex genomic data for clinicians to improve cancer treatment planning is advancing (O’Connor and McVeigh, 2025). Beyond this, a steadily growing body of AI-enabled studies now illustrates how machine-learning systems unravel scientific problems and open entirely new lines of enquiry. Jumper et al. (2021) AlphaFold-2 (Google DeepMind¹⁰) stunned the structural-biology community by predicting protein folds across whole proteomes with near-experimental accuracy, notably awarded recently the Nobel Prize in chemistry; laboratories that once spent months on crystallography can now begin functional studies immediately, accelerating everything from enzyme engineering to rare-disease research. In drug discovery, Stokes et al. (2020) used a deep neural network trained on > 100 million compounds to identify the antibiotic “halicin,” a scaffold wholly unlike existing classes, thereby rejuvenating the antibacterial pipeline at a time of mounting resistance (Boiko et al., 2023). Autonomous chemistry has taken a parallel leap: Boiko et al. combined a GPT-4-driven planner with robotic synthesis and analysis, demonstrating that a language-model agent can design, execute and interpret multi-step reactions without human intervention, effectively turning hypothesis generation and testing into a closed computational loop. On the translational frontier, Insilico Medicine’s generatively designed anti-fibrotic ISM001-055 advanced to Phase II trials in 2024—the first AI-invented small molecule to reach that milestone and a proof-of-concept for compressing pre-clinical timelines¹¹. Materials science shows a similar pattern: DeepMind’s GNoME engine used graph neural networks to predict the stability of 380,000 hitherto unknown crystals, enlarging the searchable chemical space by almost an order of magnitude and pointing experimentalists to high-value targets for batteries and quantum devices (Merchant et al., 2023).

Together these cases—from protein folding and antibiotic discovery to autonomous synthesis, AI-invented therapeutics, crystal prediction and probabilistic weather modeling—illustrate the breadth with which data-driven methods are redefining what questions scientists can ask and how quickly they can answer them.

Google DeepMind’s newly announced AlphaEvolve¹² agent pushes the idea of hypothesis generation beyond the life sciences (Gibney, 2025): by coupling Gemini large-language models to an evolutionary search loop that autonomously proposes, tests and refines code-based “hypotheses,” the system recently discovered a 48-multiplication algorithm for 4 × 4 complex-valued matrix multiplication—beating a record that had stood since 1969 and yielding double-digit speed-ups in critical AI kernels.

However, relying on AI for hypothesis generation also poses challenges related to their validation. Ensuring that these hypotheses are not only innovative but also scientifically valid and testable is crucial. There is also the need to address potential biases in the data used by LLMs, which could lead to skewed or unrepresentative hypotheses, impacting the direction and integrity of research efforts. While LLMs present exciting possibilities, their use must be carefully managed if we are to harness their full potential responsibly.

AI’s role in enhancing experimental design is pivotal in streamlining research methodologies and refining the scientific process. By suggesting optimized methodologies, identifying potential pitfalls, and recommending improvements, AI systems can substantially increase the robustness and reliability of experimental outcomes. This capability is crucial across various scientific disciplines, where the complexity of experiments often poses significant challenges in design and execution.

The integration of AI in experimental design allows for a more systematic and data-driven approach to setting up experiments. AI algorithms can simulate multiple experimental scenarios in a virtual environment before actual implementation, saving time and resources while identifying the most promising approaches for investigation. An example are AI tools developed to optimize chemical reactions in pharmaceutical research, significantly reducing trial and error (Velasco et al., 2025). AI can suggest new and simpler experimental paths based on data from previous experiments (Boiko et al., 2023). This predictive capability ensures that experiments are not only well-designed but also more likely to yield valid and reproducible results. An example of this is utilizing AI applications in designing clinical trials¹³ to identify the most effective therapeutic doses with minimal side effects, as demonstrated in recent adaptive trial simulations integrating Bayesian optimization for dose-finding in oncology.

However, the use of AI in this context also raises important considerations. The quality of outcomes from AI-assisted designs depends heavily on the underlying algorithms and the data sets used to train them. Ensuring the transparency and interpretability¹⁴ of AI decisions is essential to in maintaining trust and understanding among researchers. Moreover, there must be a balance between AI suggestions and expert human oversight to ensure that experimental designs adhere to ethical standards and scientific rigor.

AI’s profound impact on data analysis and interpretation in complex research fields such as genomics and epidemiology is reshaping the landscape of scientific discovery. By handling and interpreting vast datasets, AI systems enable researchers to identify patterns and relationships that are too subtle or complex for traditional analytical methods. The application of machine learning in genomics to predict disease susceptibility from vast genomic datasets represent examples (Wu et al., 2018; Ho et al., 2019; Long et al., 2023). This capability is crucial in areas where understanding the interplay of numerous genetic or environmental factors is essential to advancing knowledge and developing targeted interventions.

The integration of AI in these fields accelerates the research process, enhances the precision of findings, and supports more personalized approaches to treatment and prevention strategies. For example, in genomics, AI can predict gene function from DNA sequences, while in epidemiology, it can model disease spread and effectiveness of intervention strategies under various scenarios. Another example are AI-driven epidemiological models predicting the spread of infectious diseases like COVID-19 to inform public health decisions¹⁵.

However, the application of AI in data analysis also introduces significant challenges. Ensuring the accuracy and reliability of AI-generated insights requires robust algorithms and high-quality, well-curated datasets. There is also a critical need for transparency in AI methodologies to allow validation of the results by the scientific community. Moreover, ethical concerns regarding data privacy, consent, and potential biases in AI models must be rigorously addressed to maintain trust and integrity in research outcomes.

The facilitation of cross-disciplinary communication by AI models is a critical development in the landscape of scientific research. AI’s ability to translate and clarify domain-specific terminologies and concepts enhances understanding between diverse scientific communities. This advancement is particularly vital in an era where complex global challenges require integrated approaches from multiple scientific disciplines.

AI-driven tools can bridge the communication gaps that often exist between different fields by providing accurate translations of specialized language and adapting information for interdisciplinary audiences. This enables researchers from varying backgrounds to collaborate more effectively, share insights, and innovate collectively, leading to breakthroughs that might not be achievable within single-discipline silos. Microsoft’s AI translator project¹⁶, which bridges language gaps in scientific collaborations, is a prominent example of AI in this context.

However, the implementation of AI in facilitating cross-disciplinary communication also introduces several challenges. Ensuring the accuracy of translations and interpretations of complex scientific terms is paramount; misinterpretations could lead to significant misunderstandings and potentially flawed research conclusions. Additionally, there is a need to maintain an appropriate level of human oversight in the integration of AI tools to preserve the nuanced understanding that expert knowledge brings to interdisciplinary collaborations. Balancing AI assistance with expert involvement is crucial to fostering productive dialogue and innovation across scientific boundaries.

The promise that AI would deliver de-novo therapeutic molecules is materializing. AI-assisted drug discovery and design is revolutionizing the pharmaceutical industry by accelerating the identification and development of new drugs. AI platforms like AtomNet use deep learning to predict molecule behavior, speeding up drug discovery processes (Zhavoronkov et al., 2019). Utilizing AI to model biochemical processes and molecular interactions enhances the efficiency and effectiveness of drug discovery, significantly reducing the time and cost typically required to bring a new drug to market. Insilico Medicine’s fibrosis candidate entered Phase II in 2024, the first small-molecule whose scaffold and pharmacophore were generated end-to-end by deep learning²³. Their AI platform, Pharma.ai, rapidly identifies and designs novel drug candidates, specifically a promising treatment for idiopathic pulmonary fibrosis—a serious lung condition. By leveraging deep learning for simulating drug interactions and optimizing molecular structures, they significantly shortened the pre-clinical development phase. This predictive capability not only speeds up the discovery process but also improves the safety profile of developmental drugs by filtering out compounds with undesirable effects early in the process. DeepMind’s spinoff Isomorphic Labs aims to dose its first patient by late-2025²⁴. These programs succeed because they combine generative chemistry with target-identification models trained on AlphaFold2 structures and public omics repositories. They also illustrate a subtle regulatory tension: AI can shave years off pre-clinical optimization, but agencies still require explainability dossiers that reconcile black-box embeddings with pharmacological intuition. Explaining why a molecule works is becoming as important as demonstrating that it works.

AI models are transforming predictive toxicology and environmental risk assessment by enabling the prediction of the toxicological effects of chemicals with reduced reliance on physical testing. This shift not only expedites the assessment process but also enhances safety in product development and environmental protection. By simulating how chemicals interact with biological systems, AI can predict adverse effects, significantly reducing the risk to both human health and the environment. For example, in the US, the Environmental Protection Agency’s Toxicity Forecaster (ToxCast)²⁵ or information on similar chemicals can be used to predict potential toxicity of chemicals using AI. A lifetime advocating for alternatives to animal testing has taught me that reproducibility and human relevance trump tradition (Hartung, 2024). AI read-across systems trained on physicochemical descriptors and curated in-vitro datasets now predict toxicity endpoints with a fidelity that rivals or exceeds in-vivo rodent studies (Luechtefeld et al., 2018; Kleinstreuer and Hartung, 2024). The use of AI in this field allows for a broader analysis of chemical safety by processing large datasets more efficiently than traditional methods. This includes integrating diverse data types—from molecular structure to real-world exposure data—to provide a comprehensive view of potential risks. Consequently, companies can refine product formulations to mitigate harmful effects before they reach the market, and regulatory bodies can make more informed decisions regarding chemical approvals. Building on recent analyses of generative AI’s potential for sustainable toxicology (Alam et al., 2025), these models can be applied to predict chemical hazards while reducing reliance on animal testing.

However, the deployment of AI in toxicology and risk assessment comes with critical considerations. The accuracy of AI predictions depends heavily on the quality and breadth of the training data. There is also a need for transparency in AI processes to build trust among stakeholders (Hartung et al., 2025), ensuring that decisions are based on interpretability and verifiable models which create dependable and reproducible results (Kleinstreuer and Hartung, 2024). Additionally, aligning AI-driven assessments with today’s regulatory standards and updating those standards to accommodate new AI capabilities are essential for realizing the full potential of AI in environmental safety.

The integration of AI with microphysiological systems (Roth and MPS-WS Berlin, 2021) including organ-on-a-chip technology marks a significant advancement in biomedical research and pharmaceutical testing. Indeed, research on AI in organoids and organ-on-a-chip has increased by 1,500% over the last decade²⁶, a clear indication of its perceived impact. AI enhances these technologies by enabling more accurate simulations of human organ responses, which are critical for effective disease modeling and drug testing. This synergy allows for the precise manipulation and monitoring of biological processes at the microscale, leading to better predictive models of drug efficacy and toxicity.

AI’s role in optimizing the design and operation of these systems includes automating the control of experimental conditions, analyzing large volumes of data to identify patterns, and predicting outcomes of pharmacological tests with high accuracy. This not only speeds up the research process but also reduces the reliance on animal testing by providing a more relevant human-based model.

However, the application of AI in this area also presents several challenges. Ensuring that AI systems can accurately replicate complex human physiology requires sophisticated algorithms trained on diverse and high-quality data. There are also ethical considerations related to data privacy and the potential for biases in the AI models, which could affect the reliability of the simulations. Additionally, the high costs associated with developing and maintaining advanced AI-integrated organ-on-a-chip systems may limit their accessibility and widespread adoption in the scientific community.

Organ-on-chip devices once produced informative but hard-to-quantify readouts. AI solves this by extracting rich morphological embeddings and temporal signatures from high-content imaging. Increasingly, AI allows the modeling of MPS and its fine-tuning by loops of virtual and real-world experiments (Smirnova et al., 2018). The integration of microphysiological systems with deep learning analytics has seen a substantial rise in scholarly publications over the past decade, reflecting the growing convergence of bioengineering and artificial intelligence (Hartung and Smirnova, 2025). The next horizon is so-called Organoid Intelligence (Smirnova et al., 2023): neural organoids interfaced with micro-electrode arrays whose electrical activity is modulated by reinforcement-learning algorithms. Whether such “brains in a dish” remain mere models or evolve into entities that raise moral questions is a discussion we can no longer postpone (Hartung et al., 2024).

Discovery of functional materials has historically relied on intuition and costly trial-and-error. DeepMind’s GNoME project leveraged graph neural networks to propose more than 380,000 potentially stable crystal structures, dwarfing the experimental record (Merchant et al., 2023). Yet independent laboratories have so far validated fewer than 5 %, highlighting the gap between computational novelty and practical synthesis. AI remains indispensable here—particularly for inverse design conditioned on manufacturability constraints—but the GNoME episode reminds us that hype can outpace verification when metrics are ill-defined. Self-driving laboartories might help here, e.g., A-Lab was introduced as an autonomous laboratory for the solid-state synthesis of inorganic powders (Szymanski et al., 2023; Peplow, 2023).

Beyond laboratory and molecular sciences, AI is increasingly applied to climate-scale forecasting, leveraging multimodal Earth system datasets for near-real-time prediction of extreme events and long-term climate trends. Recent advances in AI-driven climate reanalysis have demonstrated substantial gains in spatiotemporal resolution and computational efficiency, enabling more accurate forecasting of tropical cyclones, heatwaves, and precipitation extremes at global scale (Kurth et al., 2023). Such models, when integrated into the scAInce paradigm, exemplify how large-scale, machine-readable environmental data can directly inform mitigation and adaptation strategies, closing the loop between scientific prediction and policy action.

An open, machine-readable publication begins with full-text that carries persistent identifiers for every cited entity—ORCID²⁹ for authors, ROR³⁰ for institutions, DOI³¹ for references, RRID³² for reagents—and continues with well-structured supplementary material. Figures link to raw image repositories; tables export as CSV (Comma-Separated Values); statistical analyses store provenance information on software version, seed and confidence intervals. The Singapore Statement on Research Integrity³³ called for transparency as early as 2010, but until recently the incentive to comply was weak. Today compliance confers a tangible performance dividend when AI systems mine the literature, making richly annotated papers more visible, more citable and ultimately more fundable.

The FAIR principles³⁴—findable, accessible, interoperable and reusable—have become a mantra, yet in practice many “FAIR” datasets are discoverable only through bespoke portals or lack harmonized ontologies. scAInce demands stricter adherence. Metadata is no longer administrative afterthought but scientific infrastructure. Higashi et al. (2024) offer a vivid proof-point: their LLM-guided refactoring engine harmonized fourteen-million sample descriptors from the Gene Expression Omnibus with near-perfect precision, turning a notorious metadata quagmire into a fully query-able knowledge graph overnight. Without controlled vocabularies, units, provenance and licensing terms, even petabyte-scale repositories remain opaque to automated reasoning. The European Open Science Cloud³⁵ has begun to enforce ontology-aligned deposition for funded projects, and major US agencies follow suit under the 2023 federal data-sharing mandate. Journals should do the same. At Frontiers in AI we now request a machine-readable data-availability statement as a condition of acceptance.

A second hallmark of scAInce is the replacement of piecemeal, idiosyncratic studies by coordinated campaigns that create megasets: large, quality-controlled datasets whose marginal cost per additional observation is low relative to their societal value. The rationale echoes evidence-based medicine: individual trials are fragile, but systematic evidence accumulates power. In toxicology, integrated testing strategies that combine high-throughput screens, computational models and selected in-vivo assays already outperform single-study paradigms (Caloni et al., 2022). Similar trends are evident in structural biology, where the AlphaFold Protein Structure Database (Varadi et al., 2024) delivers complete proteomes, and in environmental monitoring, where global biodiversity observatories generate harmonized sensor streams. AI thrives on these megasets, and in turn it exposes residual coverage gaps, guiding where next to invest experimental resources.

Once knowledge is represented as a graph—nodes for entities, edges for relations—AI can compute the value of potential new nodes. Techniques borrowed from active learning and Bayesian experimental design estimate the expected information gain of a yet-to-be-performed study. Funders can therefore allocate budgets not by topical fashion or political pressure but by information efficiency: which experiment, if executed, would shrink overall uncertainty the most? There is enormous potential in such information-gain scoring, letting review-bots rank grant applications and, in effect, price experimental uncertainty in real time. Converging evidence confirms the feasibility of that vision: Google’s newly granted patent US 11354342 B2³⁶ operationalizes an “information-gain” score for ranking documents in automated assistants, the Bayesian-experimental-design community now offers differentiable estimators of expected information gain that can steer live wet-lab protocols (Ao and Li, 2024), and the GFlowNets framework generalizes the same criterion to high-dimensional molecular and materials search—together showing that uncertainty-priced, information-efficient science already works from search engines to bench-top synthesis. The result is a virtuous cycle: comprehensive datasets feed better models; models reveal knowledge gaps; gap-driven funding yields new data that further enrich the Commons.

The epistemic currency of scAInce is machine-readable information. When data acquire clear, computable utility, market-like mechanisms become feasible. Tokenized data rights, prediction-market-inspired funding pools, and pay-for-results contracts could channel private capital into high-impact experiments while keeping outputs open. Skeptics fear enclosure of the knowledge commons, yet well-designed licenses—copyleft for data, permissive for downstream models—can reconcile investment incentives with openness. The Global Alliance for Genomics and Health³⁷ has demonstrated that federated data trusts can protect individual privacy while enabling population-scale AI analyses. Similar structures could underwrite climate models, materials databases or even large-animal toxicology surrogates.

An important dimension of equity in scAInce relates to disciplines that are inherently data-poor or rely primarily on qualitative methods, such as parts of the humanities, anthropology, certain branches of history, and emerging scientific domains still in early data-collection phases. Because the scAInce paradigm thrives on large, standardized, and machine-readable “megasets,” these fields risk marginalization if their contributions are undervalued in algorithmically optimized research agendas. This could deepen existing disparities in visibility, funding, and scholarly influence, while narrowing the epistemic diversity needed for a balanced scientific ecosystem.

Several approaches can mitigate this imbalance. First, synthetic-data generation—when transparently documented—can augment sparse datasets, enabling AI models to explore plausible scenarios without displacing the interpretive richness of original sources. Structured frameworks for synthetic data creation, spanning both quantitative and qualitative domains, have recently been proposed, with applications including synthetic populations, expert systems, and survey replacements (Timpone and Yang, 2024). Second, cross-modal transfer learning from richer domains can allow models to draw inferences even from small or unstructured corpora, for example by aligning textual, visual, and metadata representations. Third, machine-assisted “quantitizing” approaches can help transform qualitative insights into analyzable formats without eroding their contextual nuance, facilitating the integration of humanities and social science data into large-scale AI systems (Karjus, 2023). Fourth, funding earmarks and policy incentives can explicitly support the digitization, annotation, and integration of qualitative archives into interoperable formats, ensuring they remain accessible to AI systems without losing their interpretive depth. Finally, governance frameworks should monitor and report discipline-level AI adoption and impact metrics to identify early signs of exclusion. Embedding such safeguards into scAInce infrastructures will help maintain the inclusivity, interdisciplinarity, and cultural breadth that are vital to the long-term health of the scientific enterprise.

Researchers should treat machine-readable dissemination as integral to the scientific method, not as an optional post-hoc gesture. Journals must raise the bar on data and metadata deposition. Funders ought to allocate a fixed percentage of every grant to ensure FAIR compliance and to support community curators. Finally, the international policy community, building on UNESCO’s 2021 Recommendation on Open Science³⁸, should negotiate an intergovernmental accord that guarantees open, machine-readable access to publicly funded research.

The reward is immense. scAInce promises an era in which collective understanding expands not by incremental labor but by compounding returns on shared information. If we seize the opportunity, AI systems will not merely replicate existing scholarship; they will help us design its scaffolding.

Science for AI raises its own dilemmas. If citation counts already skew toward English-language journals, algorithmic optimization may amplify the imbalance, marginalizing scholars from the Global South whose work remains under-represented in major repositories. Data monopolies could emerge if access to megasets becomes paywalled or subject to opaque governance. Equally troubling is the potential erosion of serendipity: an AI that allocates funds purely by information gain might undervalue exploratory research lacking obvious immediate payoff. Governance frameworks must therefore include equity-of-access and diversity-of-approach metrics alongside efficiency scores.

A less quantifiable but equally significant concern is the potential erosion of the “spirit of science” if research agendas increasingly converge on machine-tractable problems. Left unchecked, algorithmic optimization for information gain or predictive accuracy could inadvertently deprioritize exploratory, high-risk inquiries that lack immediate computational payoff but are essential for paradigm shifts. As summarized in Table 2, scAInce differs from computational and data science in that its methodological feedback loops are often shaped by AI system capabilities; without corrective measures, this dynamic may narrow the epistemic landscape, privileging efficiency over curiosity. This narrowing of focus may reinforce existing disciplinary hierarchies, deepen inequalities between data-rich and data-poor fields, and reduce the diversity of epistemic approaches that sustains scientific resilience. To counter this tendency, governance frameworks should incorporate diversity-of-approach metrics alongside efficiency and reproducibility benchmarks, ensuring that funding and publication systems explicitly reward methodological pluralism, underrepresented research topics, and unconventional study designs. Such safeguards will help preserve the creative breadth and serendipitous discovery that have historically driven transformative advances in science.